EE32 Determining the Expected Pricing Advantage of First-in-Indication and First-in-Class Non-Oncology Orphan Products
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.333
https://www.valueinhealthjournal.com/article/S1098-3015(24)00448-0/fulltext
Title :
EE32 Determining the Expected Pricing Advantage of First-in-Indication and First-in-Class Non-Oncology Orphan Products
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00448-0&doi=10.1016/j.jval.2024.03.333
First page :
Section Title :
Open access? :
No
Section Order :
11675